Key Highlights

  • Gossamer Bio finalized a private Placement financing agreement for as much as $250 million linked to seralutinib development.
  • The deal features a $25 million upfront payment and $125 million contingent on FDA acceptance of the PAH NDA.
  • A further $100 million is tied to potential approval.
  • The financing projects a cash runway into 2028, ahead of an anticipated September 1, 2026 regulatory filing.

Gossamer Bio, Inc. (NASDAQ: GOSS) finalized a private placement financing agreement for as much as $250 million linked to seralutinib development, featuring a $25 million upfront payment and $125 million contingent on FDA acceptance of the PAH NDA.

What Happened

The deal, which includes a further $100 million upon potential approval, projects a cash runway into 2028 while introducing significant prospective share dilution before the anticipated September 1, 2026 regulatory filing.

Market Reaction

The disclosed information does not include stock price or trading data for Gossamer Bio following the financing announcement.

Outlook

The anticipated September 1, 2026 regulatory filing for seralutinib's PAH NDA represents the next major disclosed milestone tied to this financing structure.